For example, in a phase II study of adavosertib in combination with carboplatin for refractory TP53 mutated ovarian cancer, overall response rates were more than doubled to 43% in this poor outcome cancer as compared to response rates of 11% to 21% for other second-line treatments [27]. The gene discussed is TP53; the disease is ovarian carcinoma.